-5.38% to Target, Peel Hunt Maintains “Hold” Rating for Abcam PLC (LON:ABC) Stock; Fidelity & Guaranty Life (FGL) Has 0.66 Sentiment

Fidelity & Guaranty Life, through its subsidiaries, provides annuities and life insurance products in the United States. The company has market cap of $1.84 billion. It offers fixed indexed annuities, fixed rate annuities, single premium immediate annuities, and indexed universal life insurance policies. It has a 9.45 P/E ratio. The firm distributes its products to various age groups in the middle-income market through independent agents, managing general agents, and specialty brokerage firms, as well as to selected institutional markets.

London: In analysts report revealed to clients on Monday morning, Peel Hunt reaffirmed their “Hold” rating on shares of Abcam PLC (LON:ABC). They currently have a GBX 1100.00 target price per share on the company. Peel Hunt’s target gives a potential downside of -5.38% from the company’s previous close.

Omni Partners Llp holds 1.87% of its portfolio in Fidelity & Guaranty Life for 470,939 shares. Brevan Howard Capital Management Lp owns 17,348 shares or 1.24% of their US portfolio. Moreover, Gardner Lewis Asset Management L P has 0.93% invested in the company for 467,245 shares. The New York-based Water Island Capital Llc has invested 0.78% in the stock. S. Muoio & Co. Llc, a New York-based fund reported 25,000 shares.

It closed at $31.1 lastly. It is up 14.78% since January 22, 2017 and is uptrending. It has underperformed by 1.92% the S&P500.

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company has market cap of 2.39 billion GBP. The firm primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, and tools and reagents. It has a 56.52 P/E ratio. The Company’s products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics and nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells, as well as in drug discovery services and products.

Analysts await Abcam Plc (LON:ABC) to report earnings on January, 30. They expect $1.34 EPS, down 1.47% or $0.02 from last year’s $1.36 per share. ABC’s profit will be $2.73 million for 218.28 P/E if the $1.34 EPS becomes a reality. After $1.33 actual EPS reported by Abcam Plc for the previous quarter, Wall Street now forecasts 0.75% EPS growth.